Eli Lilly's most recent trend suggests a bullish bias. One trading opportunity on Eli Lilly is a Bull Put Spread using a strike $66.00 short put and a strike $61.00 long put offers a potential 11.61% return on risk over the next 17 calendar days. Maximum profit would be generated if the Bull Put Spread were to expire worthless, which would occur if the stock were above $66.00 by expiration. The full premium credit of $0.52 would be kept by the premium seller. The risk of $4.48 would be incurred if the stock dropped below the $61.00 long put strike price.
The 5-day moving average is moving up which suggests that the short-term momentum for Eli Lilly is bullish and the probability of a rise in share price is higher if the stock starts trending.
The 20-day moving average is moving up which suggests that the medium-term momentum for Eli Lilly is bullish.
The RSI indicator is at 76 level which suggests that the stock is neither overbought nor oversold at this time.
To learn how to execute such a strategy while accounting for risk and reward in the context of smart portfolio management, and see how to trade live with a successful professional trader, view more here
LATEST NEWS for Eli Lilly
Lilly's CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy
Wed, 05 Nov 2014 19:57:28 GMT
noodls – CYRAMZA now approved both as a single-agent treatment and in combination with chemotherapy Nov 5, 2014 2:49pm INDIANAPOLIS , Nov. 5, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today …
2:55 pm Eli Lilly announces FDA approval of CYRAMZA (ramucirumab) in combination with paclitaxel for the treatment of advanced gastric cancer after prior chemotherapy
Wed, 05 Nov 2014 19:55:00 GMT
Lilly's CYRAMZA® (ramucirumab) in Combination with Paclitaxel Granted FDA Approval for Advanced Gastric Cancer After Prior Chemotherapy
Wed, 05 Nov 2014 19:49:00 GMT
PR Newswire – INDIANAPOLIS, Nov. 5, 2014 /PRNewswire/ — Eli Lilly and Company (NYSE: LLY) announced today that the U.S. Food and Drug Administration (FDA) has approved CYRAMZA ® (ramucirumab) in combination with paclitaxel …
Merck takes steps to return Zilmax to U.S. cattle market
Wed, 05 Nov 2014 19:06:17 GMT
Reuters – Merck & Co. is taking steps to resume sales of its controversial cattle feed additive Zilmax by changing the way the drug is administered, hoping to recapture some market share in the beef industry, where the U.S. Food and Drug Administration has approved adjustments to the drug's label that would allow veterinarians and feedlot operators to use a lower dose and alternative method of feeding the drug to beef cattle, Merck said Wednesday. The new “component feeding” option would allow Zilmax, which can add up to 30 pounds of marketable meat to a 1,300-pound steer, to be fed in one smaller daily ration, rather than continually throughout the day, Merck nutritionist Dr. David Yates told Reuters.
GOP's health care agenda
Wed, 05 Nov 2014 18:26:00 GMT
Related Posts
Also on Market Tamer…
Follow Us on Facebook